Interim Clinical Commissioning Policy: Baricitinib for patients hospitalised due to COVID-19 (adults and children aged 2 years and over)

Document first published:
Page updated:
Publication type:

Baricitinib is recommended to be available as a treatment option through routine commissioning for adults and children (aged 2 years and over) hospitalised with COVID-19 in accordance with the criteria set out in this document.


Published 5 May 2022.